Health & Beauty

Practical tips when disaster strikes

The FINANCIAL -- Amid raging wildfires in California, and as it is entered what the National Oceanic and Atmospheric Administration calls the most active and dangerous time of year for tropical cyclone activity, heed these emergency procedure tips from doctors who have been ...

The study opens eyes to Alzheimer’s disease risk

The FINANCIAL -- Study, by University of Washington (UW) researchers, involved 3,877 adults age 65 and older, who were part of an ongoing, prospective cohort study initiated in 1994 ("Adult Changes ...

Two Phase 3 Trials of Enzalutamide in Patients with Hormone-Sensitive Prostate Cancer

The FINANCIAL -- NEW YORK and TOKYO, August 22, 2018 –Pfizer Inc. and Astellas Pharma Inc. announced amendments to the protocols for two registrational Phase 3 trials, ARCHES and EMBARK, designed ...

The Benefit of LDL-C Lowering With Repatha Across Gender and Age

The FINANCIAL -- THOUSAND OAKS, Calif. -- Amgen announced the upcoming presentation of new Repatha (evolocumab) analyses, including a late-breaking study evaluating the efficacy of Repatha in ...

Blue light hastens vision loss? ‘Not so fast

The FINANCIAL -- 'Blue light accelerates blindness,' headlines declare following new research, but doctors warn that reports of digital screen-time-induced vision loss are greatly ...

Update on TULIP 1 Phase III trial for anifrolumab

The FINANCIAL -- AstraZeneca and MedImmune, its global biologics research and development arm, announced top-line results from the TULIP 1 Phase III trial for anifrolumab in adult patients with ...

Christopher Boerner Appointed as Executive Vice President and Chief Commercial Officer in Bristol-Myers Squibb

The FINANCIAL -- PRINCETON, N.J.-- Bristol-Myers Squibb Company announced that Christopher Boerner, Ph.D., has been appointed executive vice president and chief commercial officer, effective ...

When T-cells go bad

The FINANCIAL -- Glaucomatous neurodegeneration may stem from a case of mistaken identities after high intraocular pressure (IOP) triggers an autoimmune response that targets retinal cells, new ...

Novartis combination therapy Tafinlar + Mekinist for adjuvant treatment of BRAF V600 mutation-positive melanoma

The FINANCIAL -- Basel, August 29, 2018 - Novartis announced that the European Commission (EC) has approved Tafinlar (dabrafenib) in combination with Mekinist (trametinib) for the adjuvant treatment ...

Ozempic consistently reduced the risk of major cardiovascular events

The FINANCIAL -- Ozempic (semaglutide) consistently reduced the risk of the composite outcome of time to first occurrence of non-fatal heart attack, non-fatal stroke or cardiovascular death ...

Radical transformations likely needed to achieve universal health care

The FINANCIAl -- Boston, MA – Technological innovation, expansion of the use of frontline personnel such as community health workers, and rapid increases in health care financing are likely to be ...

Other

User pages

Main Menu

Practical tips when disaster strikes

The study opens eyes to Alzheimer’s disease risk

Two Phase 3 Trials of Enzalutamide in Patients with Hormone-Sensitive Prostate Cancer

The Benefit of LDL-C Lowering With Repatha Across Gender and Age

Blue light hastens vision loss? ‘Not so fast

Update on TULIP 1 Phase III trial for anifrolumab

Christopher Boerner Appointed as Executive Vice President and Chief Commercial Officer in Bristol-Myers Squibb

When T-cells go bad

Novartis combination therapy Tafinlar + Mekinist for adjuvant treatment of BRAF V600 mutation-positive melanoma

Ozempic consistently reduced the risk of major cardiovascular events

Radical transformations likely needed to achieve universal health care

Get in Touch

Resource

Guidebook

Follow us

Terms